Ceritinib medicinal composition

A technology for ceritinib and a composition, which is applied in the field of ceritinib pharmaceutical compositions and their preparation, can solve problems such as difficulty in rapid dissolution, and achieve the effects of avoiding delayed absorption in vivo, rapid dissolution, and sufficient dissolution
CN106176752AActive Publication Date: 2016-12-07CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD
2 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD
Publication Date
2016-12-07

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a ceritinib medicinal composition. The medicinal composition contains ceritinib and at least one pharmaceutically acceptable carrier, and the raw material particle size D90 is 20-80 [mu]m. The medicinal composition has the advantages of rapid release and stable quality. The invention also relates to a preparation method of the medicinal composition. The preparation method has the advantages of simple preparation process, and suitableness for industrial large-scale production.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of medicine, and in particular relates to a ceritinib pharmaceutical composition and a preparation method thereof. Background technique

[0002] Ceritinib, English name: Ceritinib, chemical name: 5-chloro-N 4 -[2-(isopropylsulfonyl)phenyl]-N 2 -[5-Methyl-2-isopropoxy-4-(piperidin-4-yl)phenyl]-2,4-pyrimidinediamine, structural formula:

[0003] Ceritinib is an antineoplastic drug developed by Novartis. It was approved by the FDA in April 2014. The trade name is For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed or cannot be tolerated after crizotinib treatment. Ceritinib is a kinase inhibitor. The inhibitory targets of ceritinib include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR) and ROS1. Among these targets, ceritinib has the strongest activity against ALK. The ALK gene...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More